Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNB4 | O00305 | 1/20 | 0.32 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.32 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.32 |
| ▸ | CACNG3 | O60359 | 1/20 | 0.32 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.32 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.32 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.32 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.32 |
| ▸ | CACNG7 | P62955 | 1/20 | 0.32 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.32 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.32 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.32 |
| ▸ | CACNG1 | Q06432 | 1/20 | 0.32 |
| ▸ | CACNB2 | Q08289 | 1/20 | 0.32 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.32 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.32 |
| ▸ | CACNA1E | Q15878 | 1/20 | 0.32 |
| ▸ | CACNA2D4 | Q7Z3S7 | 1/20 | 0.32 |
| ▸ | CACNA2D3 | Q8IZS8 | 1/20 | 0.32 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL105894 | 0.91 | CACNB4 (0.33) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F | |
| SCHEMBL141128 | 0.89 | ACACB (0.31) | — | |
| SCHEMBL105492 | 0.77 | CACNB4 (0.34) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F | |
| SCHEMBL105107 | 0.72 | ITGB1 (0.33) | — | |
| SCHEMBL140752 | 0.70 | TTK (0.36) | — | |
| SCHEMBL17425405 | 0.69 | JAK2 (0.32) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F | |
| SCHEMBL104404 | 0.67 | TTK (0.43) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F | |
| SCHEMBL105318 | 0.67 | TTK (0.37) | — | |
| SCHEMBL105076 | 0.66 | TTK (0.34) | — | |
| SCHEMBL26741612 | 0.62 | CACNB4 (0.44) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2460805-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | Oncotherapy Science, Inc. (JP) | 2012-06-06 | — | — | EP | disclosed |
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | NR0B1, GRK7, NR5A2 | CACNB4 1292/4885CACNA1A 2870/4885CACNA1G 2069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.